The number of medical spas, weight loss clinics and concierges where patients pay a fee for immediate, often same-day access to doctors has exploded in recent years. But while patients pay for these services out of pocket, providers still often rely on software built for traditional insurance-based care.
VITLan 18-month-old startup, claims to solve one of the industry’s biggest technology problems by creating an e-prescribing platform — a digital tool for sending and managing prescriptions — tailored for cash-strapped medical businesses.
On Wednesday, VITL announced a $7.5 million Series A funding round led by SignalFire.
Founder and CEO Charlie Jordan created the Nashville-based company after realizing how much time doctors spend managing prescriptions for treatments not covered by insurance.
Many providers still rely on faxes or phone calls to send prescriptions to pharmacies, which create custom medications to order, often without knowing the final cost to the patient or how long it will take to fill the order. VITL’s platform fixes this by connecting clinics to a national network of compounding pharmacies, offering real-time price comparisons and Amazon-style order tracking.
“We’re reducing the prescription time from several minutes to a few seconds,” Jordan told TechCrunch.
For clinics that place dozens of orders each day, these time savings add up.
Techcrunch event
San Francisco, California
|
13-15 October 2026
VITL estimates that its technology saves customers up to two full business days per month by automating an otherwise cumbersome and opaque process.
Cash payment providers clearly see the value in VITL’s platform. Just over a year after its launch, the company reports that it has more than 630 clinics and is generating eight figures in annual recurring revenue (ARR), meaning the company is on pace to bring in at least $10 million annually.
That said, 630 customers represent just a fraction of a market that includes tens of thousands of clinics across the U.S. As interest in GLP-1 — the drug class that includes Ozempic and Wegovy — peptides and cosmetic procedures like Botox grows, the number of health care businesses paying cash is set to expand.
VITL never introduced SignalFire, but the startup’s rapid growth caught its attention. That interest translated into a new $7.5 million Series A round led by the venture capital firm, which is known for using data and artificial intelligence to spot breakout companies.
VITL competes in part with e-prescribing industry leader Surescripts and boutique clinical platforms such as Jane Software, which bundle prescriptive functions into broader electronic health record (EHR) software. What sets VITL apart from these competitors, he says, is its unique focus on the medical cash flow requirements.
